A Phase 1 Pharmacokinetic Study to Assess the Steady State Pharmacokinetic Profile and Short Term Safety of Maraviroc Dosed With Darunavir/Ritonavir All Once Daily, With and Without Nucleoside Analogues, in HIV-1 Infected Subjects.

Trial Profile

A Phase 1 Pharmacokinetic Study to Assess the Steady State Pharmacokinetic Profile and Short Term Safety of Maraviroc Dosed With Darunavir/Ritonavir All Once Daily, With and Without Nucleoside Analogues, in HIV-1 Infected Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2014

At a glance

  • Drugs Darunavir (Primary) ; Maraviroc (Primary) ; Ritonavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 31 Aug 2012 Status changed from recruiting to completed as reported by UKCRN.
    • 18 Aug 2012 Planned End Date changed from 1 May 2012 to 31 Aug 2012 as reported by UKCRN.
    • 18 Mar 2012 United Kingdom Clinical Research Network reports accrual to date changed from 60% to 80%.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top